Related Experiment Video
Updated: Apr 14, 2026

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions
Published on: March 14, 2016
Antagonist Binding Actively Disrupts Interleukin-1 Receptor Dynamics to Block Co-receptor Recruitment
Chandran Nithin1, Ayomide Fasemire1, Sebastian Kmiecik1
1Biological and Chemical Research Centre, Faculty of Chemistry, University of Warsaw, 02-089 Warsaw, Poland.
Abstract:
Interleukin-1 receptor type 1 (IL1R1) is a central regulator of inflammatory signaling and functions as a molecular switch, yet it remains unclear how agonists and antagonists that bind the same primary site produce opposite signaling outcomes. Available structural data define inactive and active endpoint conformations but do not explain how antagonist binding dynamically prevents co-receptor recruitment. Here, we combine all-atom molecular dynamics simulations with multiscale flexibility modeling using CABS-flex to systematically compare the intrinsic dynamics of IL1R1 across its unbound, agonist-bound, antagonist-bound, and co-receptor-bound states. Although both agonists and antagonists engage the same conserved interface on the D1/D2 domains, they induce fundamentally different dynamic responses in the receptor. Agonist binding progressively stabilizes interdomain coupling and promotes a stepwise transition toward a signaling-competent conformation. In contrast, antagonist binding selectively increases the flexibility of the distal D3 domain, particularly at the co-receptor binding interface, thereby preventing progression along the activation pathway. Importantly, the interaction patterns and dynamic signatures observed in the simulations are consistent with experimentally identified binding determinants, mutational data, and structural features associated with receptor activation and inhibition. These results demonstrate that IL1R1 antagonism is an active, allosteric, dynamics-driven process rather than a simple failure to stabilize an active conformation. Together, this work provides a mechanistic framework that reconciles existing structural and functional observations and highlights receptor dynamics as a key determinant of signaling control in the interleukin-1 system.
More Related Videos
06:56A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
Published on: March 10, 2018
09:40Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
Published on: September 28, 2018
Related Concept Videos
Drug-Receptor Interaction: Antagonist
Antagonists can be classified as competitive or noncompetitive based on their...
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Drug-Receptor Interactions
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
The Two-State Receptor Model
The binding affinity of a drug determines its interaction with...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...